Abstract
OBJECTIVESThe advent of botulinum neurotoxin type A (BoNT/A) gave rise to substantial progress in the treatment of focal dystonias. In the light of the high costs of the toxin and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have